Bristol-Myers Drops After Cancer Drug Combo Rejected in Europe

(Bloomberg) -- Bristol-Myers Squibb Co.’s euphoria from a solid second-quarter earnings report lasted less than four hours.

Bloomberg Quint

Add BloombergQuint App to Home screen.